规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO |
|
||
100mg |
|
||
500mg |
|
||
1g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
体外研究 (In Vitro) |
甘草的主要生物活性成分18β-甘草次酸具有抗炎、抗溃疡和抗增殖特性。 MTS 实验表明,用 18β-甘草次酸处理 24 小时,可以以剂量依赖性方式降低两种细胞系的细胞增殖。 160 μM 18β-甘草次酸显着降低了活细胞的比例,A549 中活细胞比例降至约 40.5±10.5%,NCI-H460 中活细胞比例降至 38.3±4.6%(分别为 p < 0.01)。当细胞用 320 μM 18β-甘草次酸处理时,细胞生长受到更大的抑制;与未处理的对照相比,活细胞的比例低于 30% (p<0.001)。用 160 μM 和 320 μM 18β-甘草次酸处理后,全长 PARP 水平下降,而裂解 PARP 水平上升 [1]。
|
||
---|---|---|---|
体内研究 (In Vivo) |
给予小剂量18β-甘草次酸(50 mg/kg)的大鼠的三项血清参数均显着低于18β-甘草次酸+雷公藤甲素(TP)组的TP大鼠。 18β-甘草次酸+TP组大鼠给予高剂量(100mg/kg)药物后,三种肝酶水平有所下降。与TP组相比,没有统计学上显着的下降。另一方面,当预先给予低剂量的18β-甘草次酸时,小鼠不会受到TP引起的肝损伤。相比之下,低剂量18β-甘草次酸(50 mg/kg)显着抑制上述四种细胞因子的产生[3]。
|
||
动物实验 |
|
||
参考文献 |
[1]. Huang RY, et al. 18β-Glycyrrhetinic acid suppresses cell proliferation through inhibiting thromboxane synthase in non-small cell lung cancer. PLoS One. 2014 Apr 2;9(4):e93690.
[2]. Zhou J, et al. 18β-glycyrrhetinic acid suppresses experimental autoimmune encephalomyelitis through inhibition of microglia activation and promotion of remyelination. Sci Rep. 2015 Sep 2;5:13713. [3]. Yang G, et al. Protective Effect of 18β-Glycyrrhetinic Acid against Triptolide-Induced Hepatotoxicity in Rats. Evid Based Complement Alternat Med. 2017;2017:3470320 |
分子式 |
C30H46O4
|
|
---|---|---|
分子量 |
470.68
|
|
CAS号 |
471-53-4
|
|
相关CAS号 |
|
|
SMILES |
CC(C)([C@](CC[C@@]([C@@]1(CC[C@]2(CC[C@](C(O)=O)(C[C@]2(C1=C3)[H])C)C)C)4C)5[H])[C@@H](O)CC[C@]5(C)[C@@]4([H])C3=O
|
|
InChi Key |
MPDGHEJMBKOTSU-YKLVYJNSSA-N
|
|
InChi Code |
InChI=1S/C30H46O4/c1-25(2)21-8-11-30(7)23(28(21,5)10-9-22(25)32)20(31)16-18-19-17-27(4,24(33)34)13-12-26(19,3)14-15-29(18,30)6/h16,19,21-23,32H,8-15,17H2,1-7H3,(H,33,34)/t19-,21-,22-,23+,26+,27-,28-,29+,30+/m0/s1
|
|
化学名 |
(2S,4aS,6aS,6bR,8aR,10S,12aS,12bR,14bR)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid
|
|
别名 |
Glycyrrhetin; Enoxolone; Glycyrrhetic acid; BRN 2229654; NSC 35347; NSC-35347; BRN-2229654; BRN2229654; NSC35347
|
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
|
|||
---|---|---|---|---|
溶解度 (体内) |
Solubility in Formulation 1: ≥ 2.17 mg/mL (4.61 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.17 mg/mL (4.61 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 2% DMSO+30% PEG 300+5% Tween 80+ddH2O: 10mg/mL 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 2.1246 mL | 10.6229 mL | 21.2459 mL | |
5 mM | 0.4249 mL | 2.1246 mL | 4.2492 mL | |
10 mM | 0.2125 mL | 1.0623 mL | 2.1246 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05987722 | Completed | Other: Enoxolone Other: Sensodyne |
Periodontal Surgery | Kaohsiung Medical University Chung-Ho Memorial Hospital |
July 30, 2021 | Not Applicable |
NCT05570110 | Recruiting | Drug: Enoxolone | Unipolar Depression | Philipps University Marburg Medical Center |
September 23, 2022 | Phase 1 Phase 2 |
NCT03874949 | Completed | Device: SEALITE Regular Device: SEALITE Ultra |
Root Canal Obturation | ACTEON Group | April 2, 2019 | Not Applicable |
NCT00384384 | Completed | Drug: oral 18B Glycyrrhetinic acid versus placebo |
End Stage Renal Disease | Insel Gruppe AG, University Hospital Bern |
August 2006 | Phase 2 |